prIME Symposium on SCCHN and CRC

prIME Symposium on SCCHN and CRC

Applying New Evidence to Patient Care

Not a member of My prIME? Join now for instant access.

This meeting is only intended for physicians from the Latin American region.

Meeting Overview

The prIME Symposium on SCCHN and CRC will update participants about the latest advances and emerging strategies in the management of head & neck cancer and advanced colorectal cancer (CRC) how to translate new evidence into clinical practice. In addition to didactic presentations, this program will feature interactive quiz questions and discussion of clinical cases with expert faculty.

Date and Location

Saturday, 5 May 2018
08.00 – 17.00

Hilton Barra Rio de Janeiro
Av. Aberlado Bueno
1430 Barra da Tijuca
Rio de Janeiro, Brazil



Saturday, 5 May 2018
08.00 – 17.00



Rio de Janeiro, Brazil



08.00 Registration and welcome coffee
08.30 Introduction and demographics
Raúl E. Giglio, MD; André Deeke Sasse, MD, PhD; prIME Medical Director

Keynote Presentation

08.40 Cancer immunotherapy: Key principles, concepts, and clinical applications
Cristina Bonorino, PhD
09.10 Audience questions and faculty comments

Session 1: Head & Neck Cancer
Session Chair: Raúl Giglio, MD

09.20 Quiz: Are you up-to-date with recent advances in head and neck cancer?
09.30 Locally advanced squamous cell carcinoma of the head and neck (SCCHN): Individualized treatment approach
Aline Lauda Freitas Chaves, MD, MBA, MSc
09.55 Audience questions and faculty comments
10.05 Optimal treatment of recurrent/metastatic SCCHN: Front-line therapy and beyond
Raúl E. Giglio, MD
10.30 Audience questions and faculty comments
10.40 Coffee break
11.00 How I treat SCCHN: Interactive case-based discussion
Kevin Harrington, MBBS, PhD, FRCT, FRCR
Fabiane Cesario, MD
11.45 Head and neck cancer management in the coming years: What can we expect?
Kevin Harrington, MBBS, PhD, FRCP, FRCR
12.05 Quiz questions revisited and faculty panel commentary
12.15 prIME Points™
Raúl E. Giglio, MD
12.20 Lunch

Session 2: Colorectal Cancer
Session Chair: Andre Deeke Sasse, MD, PhD

13.20 Quiz: Are you up-to-date with recent advances in metastatic colorectal cancer (mCRC)?
13.30 Improving outcomes in mCRC: Impact of clinical and molecular markers
Clara Montagut, MD, PhD
13.55 Audience questions and faculty comments
14.05 Metastatic CRC with unresectable liver-only metastases: Multidisciplinary treatment approach
André Deeke Sasse, MD, PhD
14.30 Audience questions and faculty comments
14.40 Managing mCRC across the disease continuum: Front-line therapy and treatment beyond progression
Guillermo Méndez, MD
15.10 Audience questions and faculty comments
15.20 Coffee break
15.40 How I treat CRC: Interactive case-based discussion
André Deeke Sasse, MD, PhD
Guillermo Méndez, MD
16.25 Colorectal cancer in the coming years: What can we expect?
Clara Montagut, MD, PhD
16.45 Quiz questions revisited
16.55 prIME Points™
André Deeke Sasse, MD, PhD
17.00 Adjourn



  • Raúl E. Giglio, MDInstituto de Oncologia Angel H Roffo
    Buenos Aires, Argentina
  • André Deeke Sasse, MD, PhDSasse Oncology and Hematology Group (SOnHe)
    Campinas, Brazil
  • Faculty

  • Cristina Bonorino, PhDPontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
    Porto Alegre, Brazil
  • Aline Lauda Freitas Chaves, MD, MBA, MScDom Oncologia
    Divinópolis, Brazil
  • Kevin Harrington, MBBS, PhD, FRCP, FRCRInstitute of Cancer Research
    London, United Kingdom
  • Guillermo Méndez, MDHospital de Gastroenterologia Bonorino Udaondo
    Buenos Aires, Argentina
  • Clara Montagut, MD, PhDHospital del Mar
    Barcelona, Spain
    Memorial Sloan Kettering Cancer Center
    New York, New York, United States

This educational activity is specifically designed for medical oncologists, radiation oncologists, head and neck surgeons/otolaryngologists, and other healthcare professionals from the Latin American region interested and/or involved in the treatment of patients with head & neck cancer and colorectal cancer (CRC).

After successful completion of this educational activity, participants should be able to:

  • Describe immunotherapeutic principles and the evolving role of immunotherapy for the management of cancer, including squamous cell carcinoma of the head and neck (SCCHN) and metastatic CRC (mCRC)
  • Apply multidisciplinary approaches for managing HPV+ and HPV-, locally advanced SCCHN
  • Identify optimal treatment sequence for patients with recurrent/metastatic SCCHN
  • Explain state-of-the-art management of mCRC, and role of biomarkers to guide personalized therapy
  • Select optimal front-line therapy for individual patient with mCRC, including those with liver-only metastases and determine best treatment sequence after disease progression

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.